Sat, Aug 30, 2014, 2:34 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Tekmira Pharmaceuticals Corp Message Board

biglabowski99 3 posts  |  Last Activity: Aug 15, 2014 10:58 PM Member since: Jun 30, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • biglabowski99 by biglabowski99 Aug 15, 2014 10:58 PM Flag

    (8/15/14) Update on the anti-CD47 cancer therapy clinical trials

    The phase-1 clinical trial of the anti-CD47 antibody is designed to test its safety. The trial will accrue one patient per month at very low doses, and the first groups of participants have been identified from among current Stanford Cancer patients. Currently we are not recruiting new patients to this trial.

    If enrollments do open up in the future, that information will be posted on this page. When and if enrollments open up, potential inclusion in this phase-1 trial will be based solely on physician referrals. If there are openings for new participants, and if you meet certain requirements, information posted on this page will describe how your physician can submit a request to the clinical trials team to consider your participation.

    Given the limited nature of this safety trial, we urge that patients not delay or forgo recommended treatments in hopes of participating in this research effort.

  • Reply to

    Stanford CD47 to start in patients in 30 days

    by biglabowski99 Jun 29, 2014 9:06 AM
    biglabowski99 biglabowski99 Jul 7, 2014 8:35 PM Flag

    being that we are basically one of the only publicly traded companies that has cd47 in the near term pipeline any sort of efficacy would be a positive and read through to trillium.

  • “Thirty days from now, the first cancer patient will be treated at Stanford,” Weissman said.

    google: McLaughlin Research Institute conference highlights ingenuity

TKMR
21.40+0.64(+3.08%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.